CN114401749A - 一种放射性核素标记物及其应用 - Google Patents

一种放射性核素标记物及其应用 Download PDF

Info

Publication number
CN114401749A
CN114401749A CN202180004915.8A CN202180004915A CN114401749A CN 114401749 A CN114401749 A CN 114401749A CN 202180004915 A CN202180004915 A CN 202180004915A CN 114401749 A CN114401749 A CN 114401749A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
diastereomer
enantiomer
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180004915.8A
Other languages
English (en)
Other versions
CN114401749B (zh
Inventor
王倩倩
王宇
吴方舟
吴然
王雷
宋紫辉
李振虎
王梦哲
郭飞虎
韩贝贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Hengrui Pharmaceutical Co ltd
Beijing Tuojie Biomedical Technology Co ltd
Original Assignee
Tianjin Hengrui Pharmaceutical Co ltd
Beijing Tuojie Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hengrui Pharmaceutical Co ltd, Beijing Tuojie Biomedical Technology Co ltd filed Critical Tianjin Hengrui Pharmaceutical Co ltd
Publication of CN114401749A publication Critical patent/CN114401749A/zh
Application granted granted Critical
Publication of CN114401749B publication Critical patent/CN114401749B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

一种式(I)所示的化合物，或其可用药盐，或其对映异构体、非对映异构体或其氘元素取代物；该化合物通过与放射性核素络合，可以与肿瘤中高表达的生长抑素受体(SSTR)结合，能够高选择性地定位到SSTR阳性的肿瘤组织中，达到疾病靶向诊断和治疗的目的。

Description

PCT国内申请，说明书已公开。

Claims (33)

  1. PCT国内申请，权利要求书已公开。
CN202180004915.8A 2020-06-29 2021-06-29 一种放射性核素标记物及其应用 Active CN114401749B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010607327 2020-06-29
CN2020106073270 2020-06-29
PCT/CN2021/103005 WO2022002022A1 (zh) 2020-06-29 2021-06-29 一种放射性核素标记物及其应用

Publications (2)

Publication Number Publication Date
CN114401749A true CN114401749A (zh) 2022-04-26
CN114401749B CN114401749B (zh) 2024-04-16

Family

ID=79317478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180004915.8A Active CN114401749B (zh) 2020-06-29 2021-06-29 一种放射性核素标记物及其应用

Country Status (3)

Country Link
CN (1) CN114401749B (zh)
TW (1) TW202214674A (zh)
WO (1) WO2022002022A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984255A (zh) * 2022-05-31 2022-09-02 苏州大学 一种放射性核素标记的PSMA-αvβ3双靶点偶联体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6123916A (en) * 1990-02-22 2000-09-26 Novartis Ag Therapeutic use of somatostatin peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337599A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP1717247A1 (en) * 2005-04-28 2006-11-02 Schering AG Cyclic peptides binding to the somatostatin receptor
CN105384807A (zh) * 2005-12-14 2016-03-09 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
US20090016989A1 (en) * 2007-04-25 2009-01-15 Frank Leu Antibodies to human somatostatin receptor and methods of use
ES2814952T3 (es) * 2012-09-04 2021-03-29 Celgene Corp Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
SG10201913964QA (en) * 2015-06-25 2020-03-30 Advanced Accelerator Applications Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
KR20220147720A (ko) * 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6123916A (en) * 1990-02-22 2000-09-26 Novartis Ag Therapeutic use of somatostatin peptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984255A (zh) * 2022-05-31 2022-09-02 苏州大学 一种放射性核素标记的PSMA-αvβ3双靶点偶联体及其应用
CN114984255B (zh) * 2022-05-31 2023-09-26 苏州大学 一种放射性核素标记的PSMA-αvβ3双靶点偶联体及其应用

Also Published As

Publication number Publication date
CN114401749B (zh) 2024-04-16
TW202214674A (zh) 2022-04-16
WO2022002022A1 (zh) 2022-01-06

Similar Documents

Publication Publication Date Title
EP3089992B1 (en) Compositions and methods for imaging cancer
KR100689402B1 (ko) 기본구조에 고리가 형성된 소마토스태틴 유사체
CN114401749B (zh) 一种放射性核素标记物及其应用
DE60038739T2 (de) Somatostatin analoge, deren radiomarkierte derivate und deren verwendung
US20040102364A1 (en) Backbone cyclized radiolabelled somatostatin analogs
WO2005018682A2 (en) Somatostatin analogs with inhibitory activity to growth hormone release
Wang et al. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate
US20070066516A1 (en) Compounds comprising cyclized somatostatin receptor binding peptides
WO2008138141A1 (en) Labelled adrenomedullin derivatives and their use for imaging and therapy.
US20050118099A1 (en) Thiol-mediated drug attachment to targeting peptides
EP1257575B1 (en) Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
JP4318985B2 (ja) ソマトスタチンアナログ誘導体およびその利用
US20050226813A1 (en) Labelled somatostatin analogs backbone cyclized through metal complexation
US20120259092A1 (en) Npy antagonists
WO2021198229A1 (en) Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes
WO2006114324A1 (en) Compounds comprising cyclized somatostatin receptor binding peptides
WO2005123761A1 (en) GnRH ANALOGS BACKBONE CYCLIZED THROUGH METAL COMPLEXATION

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant